Compare Stocks: SANA, VKTX, LEGN, and AMLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$32.41 -4.5%	$27.21	$10.83 ▼ $41.14	$3.78B	-0.13	1.91 million shs	2.05 million shs
LEGN Legend Biotech	$17.61 +0.2%	$20.76	$16.24 ▼ $37.50	$3.41B	0.4	1.83 million shs	2.94 million shs
SANA Sana Biotechnology	$3.10	$3.50	$2.61 ▼ $6.55	$928.02M	2.12	3.15 million shs	7.41 million shs
VKTX Viking Therapeutics	$28.99 -1.3%	$33.87	$24.52 ▼ $43.15	$3.42B	0.69	1.82 million shs	2.66 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-4.51%	+2.50%	-16.04%	+106.83%	+153.80%
LEGN Legend Biotech	+0.17%	-5.53%	-22.08%	-36.95%	-48.91%
SANA Sana Biotechnology	0.00%	-0.96%	-24.39%	-1.59%	+1.97%
VKTX Viking Therapeutics	-1.26%	-9.35%	-19.43%	-4.58%	+25.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$32.41 -4.5%	$27.21	$10.83 ▼ $41.14	$3.78B	-0.13	1.91 million shs	2.05 million shs
LEGN Legend Biotech	$17.61 +0.2%	$20.76	$16.24 ▼ $37.50	$3.41B	0.4	1.83 million shs	2.94 million shs
SANA Sana Biotechnology	$3.10	$3.50	$2.61 ▼ $6.55	$928.02M	2.12	3.15 million shs	7.41 million shs
VKTX Viking Therapeutics	$28.99 -1.3%	$33.87	$24.52 ▼ $43.15	$3.42B	0.69	1.82 million shs	2.66 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-4.51%	+2.50%	-16.04%	+106.83%	+153.80%
LEGN Legend Biotech	+0.17%	-5.53%	-22.08%	-36.95%	-48.91%
SANA Sana Biotechnology	0.00%	-0.96%	-24.39%	-1.59%	+1.97%
VKTX Viking Therapeutics	-1.26%	-9.35%	-19.43%	-4.58%	+25.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$38.86	19.89% Upside
LEGN Legend Biotech	2.47	Hold	$53.14	201.78% Upside
SANA Sana Biotechnology	2.80	Moderate Buy	$9.33	201.08% Upside
VKTX Viking Therapeutics	2.75	Moderate Buy	$96.63	233.30% Upside

Current Analyst Ratings Breakdown

Latest SANA, VKTX, LEGN, and AMLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/11/2026	LEGN Legend Biotech	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$78.00 ➝ $74.00
9/4/2026	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$65.00
9/4/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
9/1/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$55.00 ➝ $57.00
8/24/2026	SANA Sana Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/19/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $55.00
8/19/2026	AMLX Amylyx Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$28.00 ➝ $52.00
8/18/2026	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $42.00
8/18/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	41.33	N/A	N/A	$2.78 per share	11.66
LEGN Legend Biotech	$1.03B	3.32	N/A	N/A	$5.43 per share	3.24
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$5.65 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
LEGN Legend Biotech	-$296.80M	-$0.25	N/A	15.05	N/A	-7.21%	-8.71%	-5.40%	11/11/2026 (Estimated)
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-103.02%	-39.16%	11/5/2026 (Estimated)
VKTX Viking Therapeutics	-$359.64M	-$4.66	N/A	N/A	N/A	N/A	-94.56%	-82.75%	10/28/2026 (Estimated)

Latest SANA, VKTX, LEGN, and AMLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
8/10/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	-$1.10	+$0.11	-$1.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
LEGN Legend Biotech	N/A	3.04	2.94
SANA Sana Biotechnology	N/A	1.38	1.38
VKTX Viking Therapeutics	N/A	4.72	4.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
LEGN Legend Biotech	70.89%
SANA Sana Biotechnology	88.23%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	10.90%
LEGN Legend Biotech	0.02%
SANA Sana Biotechnology	25.40%
VKTX Viking Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	136	111.42 million	99.28 million	Optionable
LEGN Legend Biotech	2,965	193.77 million	193.73 million	Optionable
SANA Sana Biotechnology	142	299.36 million	223.32 million	Optionable
VKTX Viking Therapeutics	65	116.65 million	110.47 million	Optionable

SANA, VKTX, LEGN, and AMLX Headlines

Recent News About These Companies

4 Biotech Stocks to Watch as Potential Takeover Targets

September 18 at 1:35 PM | zacks.com

Baird Financial Group Inc. Makes New Investment in Viking Therapeutics, Inc. $VKTX

September 18 at 3:04 AM | marketbeat.com

LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?

September 17 at 12:11 PM | zacks.com

Viking Therapeutics: 3 Things To Watch In The Maintenance Data

September 17 at 10:45 AM | seekingalpha.com

Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic.

September 17 at 10:29 AM | fool.com

Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note

September 16 at 10:52 PM | finance.yahoo.com

Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note

September 16 at 6:46 PM | zacks.com

Engineers Gate Manager LP Makes New Investment in Viking Therapeutics, Inc. $VKTX

September 16 at 4:07 AM | marketbeat.com

What's Going On With the Dip in Viking Therapeutics Stock?

September 15, 2026 | benzinga.com

Can Viking Therapeutics Beat Big Pharma With Monthly Weight-Loss Shots? Here’s The Risk CEO Says Could Derail It

September 15, 2026 | stocktwits.comS

Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss

September 14, 2026 | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?

September 14, 2026 | finance.yahoo.com

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

September 11, 2026 | finance.yahoo.com

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

September 11, 2026 | zacks.com

WINTON GROUP Ltd Takes $3.53 Million Position in Viking Therapeutics, Inc. $VKTX

September 11, 2026 | marketbeat.com

Viking Therapeutics Aims High at $92 Target, But Clinical Risks Remain

September 10, 2026 | nai500.comN

Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors

September 10, 2026 | finance.yahoo.com

Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors

September 10, 2026 | zacks.com

Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.

September 10, 2026 | fool.com

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

September 9, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA, VKTX, LEGN, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$32.41 -1.53 (-4.51%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$33.18 +0.78 (+2.39%)

As of 09/18/2026 07:53 PM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Legend Biotech NASDAQ:LEGN

$17.61 +0.03 (+0.17%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$17.73 +0.12 (+0.65%)

As of 09/18/2026 07:41 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Sana Biotechnology NASDAQ:SANA

$3.10 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.09 -0.01 (-0.32%)

As of 09/18/2026 07:51 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Viking Therapeutics NASDAQ:VKTX

$28.99 -0.37 (-1.26%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$28.94 -0.04 (-0.16%)

As of 09/18/2026 07:59 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SANA, VKTX, LEGN, and AMLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SANA, VKTX, LEGN, and AMLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SANA, VKTX, LEGN, and AMLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA, VKTX, LEGN, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Legend Biotech NASDAQ:LEGN

Sana Biotechnology NASDAQ:SANA

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SANA, VKTX, LEGN, and AMLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SANA, VKTX, LEGN, and AMLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SANA, VKTX, LEGN, and AMLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA, VKTX, LEGN, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Legend Biotech NASDAQ:LEGN

Sana Biotechnology NASDAQ:SANA

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools